APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

IL-17 Inhibitors for Psoriasis

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global IL-17 Inhibitors for Psoriasis Industry Growth and Trends Forecast to 2032

Report ID 174001600128 December 202599 pages

Choose your research edition.

Industry ResearchIL-17 Inhibitors for Psoriasis Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal IL-17 Inhibitors for Psoriasis Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal IL-17 Inhibitors for Psoriasis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal IL-17 Inhibitors for Psoriasis Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal IL-17 Inhibitors for Psoriasis Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global IL-17 Inhibitors for Psoriasis market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for IL-17 Inhibitors for Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for IL-17 Inhibitors for Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for IL-17 Inhibitors for Psoriasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of IL-17 Inhibitors for Psoriasis include UCB, Kyowa Kirin, LEO Pharma, Ortho Dermatologics, Jiangsu Hengrui Pharmaceuticals, Eli Lilly, Novartis and Chongqing Genrix Biopharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global IL-17 Inhibitors for Psoriasis market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The IL-17 Inhibitors for Psoriasis market size, estimates, and forecasts are presented in terms of sales volume (Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global IL-17 Inhibitors for Psoriasis market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to IL-17 Inhibitors for Psoriasis.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global IL-17 Inhibitors for Psoriasis market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

IL-17 Inhibitors for Psoriasis Market by Company

UCB

Kyowa Kirin

LEO Pharma

Ortho Dermatologics

Jiangsu Hengrui Pharmaceuticals

Eli Lilly

Novartis

Chongqing Genrix Biopharmaceutical

IL-17 Inhibitors for Psoriasis Segment by Type

Ixekizumab

Secukinumab

Xeligekimab

Vunakizumab

Brodalumab

Bimelizumab

Other

IL-17 Inhibitors for Psoriasis Segment by Application

Hospital and Clinic

Pharmacy

Other

IL-17 Inhibitors for Psoriasis Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global IL-17 Inhibitors for Psoriasis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of IL-17 Inhibitors for Psoriasis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of IL-17 Inhibitors for Psoriasis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of IL-17 Inhibitors for Psoriasis manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of IL-17 Inhibitors for Psoriasis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Ixekizumab Table 2. Major Company of Secukinumab Table 3. Major Company of Xeligekimab Table 4. Major Company of Vunakizumab Table 5. Major Company of Brodalumab Table 6. Major Company of Bimelizumab Table 7. Major Company of Other Table 8. Global IL-17 Inhibitors for Psoriasis Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 9. Global IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026) & (Units) Table 10. Global IL-17 Inhibitors for Psoriasis Sales Market Share in Volume by Type (2021-2026) Table 11. Global IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026) & (US$ Million) Table 12. Global IL-17 Inhibitors for Psoriasis Sales Market Share in Value by Type (2021-2026) Table 13. Global IL-17 Inhibitors for Psoriasis Price by Type (2021-2026) & (US$/Unit) Table 14. Global IL-17 Inhibitors for Psoriasis Sales by Type (2027-2032) & (Units) Table 15. Global IL-17 Inhibitors for Psoriasis Sales Market Share in Volume by Type (2027-2032) Table 16. Global IL-17 Inhibitors for Psoriasis Sales by Type (2027-2032) & (US$ Million) Table 17. Global IL-17 Inhibitors for Psoriasis Sales Market Share in Value by Type (2027-2032) Table 18. Global IL-17 Inhibitors for Psoriasis Price by Type (2027-2032) & (US$/Unit) Table 19. North America IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026) & (Units) Table 20. North America IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026) & (US$ Million) Table 21. Europe IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026) & (Units) Table 22. Europe IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026) & (US$ Million) Table 23. Asia-Pacific IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026) & (Units) Table 24. Asia-Pacific IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026) & (US$ Million) Table 25. Latin America IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026) & (Units) Table 26. Latin America IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026) & (US$ Million) Table 27. Middle East and Africa IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026) & (Units) Table 28. Middle East and Africa IL-17 Inhibitors for Psoriasis Sales by Type (2021-2026) & (US$ Million) Table 29. IL-17 Inhibitors for Psoriasis Industry Trends Table 30. IL-17 Inhibitors for Psoriasis Industry Drivers Table 31. IL-17 Inhibitors for Psoriasis Industry Opportunities and Challenges Table 32. IL-17 Inhibitors for Psoriasis Industry Restraints Table 33. Global IL-17 Inhibitors for Psoriasis Sales Revenue by Company (US$ Million) & (2021-2026) Table 34. Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Company (2021-2026) Table 35. Global IL-17 Inhibitors for Psoriasis Sales by Company (2021-2026) & (Units) Table 36. Global IL-17 Inhibitors for Psoriasis Sales Share by Company (2021-2026) Table 37. Global IL-17 Inhibitors for Psoriasis Market Price by Company (2021-2026) & (US$/Unit) Table 38. Global IL-17 Inhibitors for Psoriasis Industry Company Ranking, 2024 VS 2025 VS 2026 Table 39. Global IL-17 Inhibitors for Psoriasis Major Company Production Sites and Headquarters Table 40. Global IL-17 Inhibitors for Psoriasis Company, Product Type & Application Table 41. Global IL-17 Inhibitors for Psoriasis Company Establishment Date Table 42. Global Company Market Concentration Ratio (CR5 and HHI) Table 43. Global IL-17 Inhibitors for Psoriasis by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 44. Global IL-17 Inhibitors for Psoriasis Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 45. Global IL-17 Inhibitors for Psoriasis Sales by Region (2021-2026) & (Units) Table 46. Global IL-17 Inhibitors for Psoriasis Sales Market Share in Volume by Region (2021-2026) Table 47. Global IL-17 Inhibitors for Psoriasis Sales by Region (2021-2026) & (US$ Million) Table 48. Global IL-17 Inhibitors for Psoriasis Sales Market Share in Value by Region (2021-2026) Table 49. Global IL-17 Inhibitors for Psoriasis Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 50. Global IL-17 Inhibitors for Psoriasis Sales by Region (2027-2032) & (Units) Table 51. Global IL-17 Inhibitors for Psoriasis Sales Market Share in Volume by Region (2027-2032) Table 52. Global IL-17 Inhibitors for Psoriasis Sales by Region (2027-2032) & (US$ Million) Table 53. Global IL-17 Inhibitors for Psoriasis Sales Market Share in Value by Region (2027-2032) Table 54. Global IL-17 Inhibitors for Psoriasis Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 55. Global IL-17 Inhibitors for Psoriasis Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 56. Global IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026) & (Units) Table 57. Global IL-17 Inhibitors for Psoriasis Sales Market Share in Volume by Application (2021-2026) Table 58. Global IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026) & (US$ Million) Table 59. Global IL-17 Inhibitors for Psoriasis Sales Market Share in Value by Application (2021-2026) Table 60. Global IL-17 Inhibitors for Psoriasis Price by Application (2021-2026) & (US$/Unit) Table 61. Global IL-17 Inhibitors for Psoriasis Sales by Application (2027-2032) & (Units) Table 62. Global IL-17 Inhibitors for Psoriasis Sales Market Share in Volume by Application (2027-2032) Table 63. Global IL-17 Inhibitors for Psoriasis Sales by Application (2027-2032) & (US$ Million) Table 64. Global IL-17 Inhibitors for Psoriasis Sales Market Share in Value by Application (2027-2032) Table 65. Global IL-17 Inhibitors for Psoriasis Price by Application (2027-2032) & (US$/Unit) Table 66. North America IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026) & (Units) Table 67. North America IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026) & (US$ Million) Table 68. Europe IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026) & (Units) Table 69. Europe IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026) & (US$ Million) Table 70. Asia-Pacific IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026) & (Units) Table 71. Asia-Pacific IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026) & (US$ Million) Table 72. Latin America IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026) & (Units) Table 73. Latin America IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026) & (US$ Million) Table 74. Middle East and Africa IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026) & (Units) Table 75. Middle East and Africa IL-17 Inhibitors for Psoriasis Sales by Application (2021-2026) & (US$ Million) Table 76. UCB Company Information Table 77. UCB Business Overview Table 78. UCB IL-17 Inhibitors for Psoriasis Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. UCB IL-17 Inhibitors for Psoriasis Product Portfolio Table 80. UCB Recent Development Table 81. Kyowa Kirin Company Information Table 82. Kyowa Kirin Business Overview Table 83. Kyowa Kirin IL-17 Inhibitors for Psoriasis Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Kyowa Kirin IL-17 Inhibitors for Psoriasis Product Portfolio Table 85. Kyowa Kirin Recent Development Table 86. LEO Pharma Company Information Table 87. LEO Pharma Business Overview Table 88. LEO Pharma IL-17 Inhibitors for Psoriasis Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. LEO Pharma IL-17 Inhibitors for Psoriasis Product Portfolio Table 90. LEO Pharma Recent Development Table 91. Ortho Dermatologics Company Information Table 92. Ortho Dermatologics Business Overview Table 93. Ortho Dermatologics IL-17 Inhibitors for Psoriasis Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Ortho Dermatologics IL-17 Inhibitors for Psoriasis Product Portfolio Table 95. Ortho Dermatologics Recent Development Table 96. Jiangsu Hengrui Pharmaceuticals Company Information Table 97. Jiangsu Hengrui Pharmaceuticals Business Overview Table 98. Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Product Portfolio Table 100. Jiangsu Hengrui Pharmaceuticals Recent Development Table 101. Eli Lilly Company Information Table 102. Eli Lilly Business Overview Table 103. Eli Lilly IL-17 Inhibitors for Psoriasis Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Eli Lilly IL-17 Inhibitors for Psoriasis Product Portfolio Table 105. Eli Lilly Recent Development Table 106. Novartis Company Information Table 107. Novartis Business Overview Table 108. Novartis IL-17 Inhibitors for Psoriasis Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Novartis IL-17 Inhibitors for Psoriasis Product Portfolio Table 110. Novartis Recent Development Table 111. Chongqing Genrix Biopharmaceutical Company Information Table 112. Chongqing Genrix Biopharmaceutical Business Overview Table 113. Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Product Portfolio Table 115. Chongqing Genrix Biopharmaceutical Recent Development Table 116. North America IL-17 Inhibitors for Psoriasis Market Size Growth Rate (CAGR) by Country (Units): 2021 VS 2025 VS 2032 Table 117. North America IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026) & (Units) Table 118. North America IL-17 Inhibitors for Psoriasis Sales Market Share by Country (2021-2026) Table 119. North America IL-17 Inhibitors for Psoriasis Sales Forecast by Country (2027-2032) & (Units) Table 120. North America IL-17 Inhibitors for Psoriasis Sales Market Share Forecast by Country (2027-2032) Table 121. North America IL-17 Inhibitors for Psoriasis Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 122. North America IL-17 Inhibitors for Psoriasis Market Size by Country (2021-2026) & (US$ Million) Table 123. North America IL-17 Inhibitors for Psoriasis Market Share by Country (2021-2026) Table 124. North America IL-17 Inhibitors for Psoriasis Market Size Forecast by Country (2027-2032) & (US$ Million) Table 125. North America IL-17 Inhibitors for Psoriasis Market Share Forecast by Country (2027-2032) Table 126. Europe IL-17 Inhibitors for Psoriasis Market Size Growth Rate (CAGR) by Country (Units): 2021 VS 2025 VS 2032 Table 127. Europe IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026) & (Units) Table 128. Europe IL-17 Inhibitors for Psoriasis Sales Market Share by Country (2021-2026) Table 129. Europe IL-17 Inhibitors for Psoriasis Sales Forecast by Country (2027-2032) & (Units) Table 130. Europe IL-17 Inhibitors for Psoriasis Sales Market Share Forecast by Country (2027-2032) Table 131. Europe IL-17 Inhibitors for Psoriasis Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 132. Europe IL-17 Inhibitors for Psoriasis Market Size by Country (2021-2026) & (US$ Million) Table 133. Europe IL-17 Inhibitors for Psoriasis Market Share by Country (2021-2026) Table 134. Europe IL-17 Inhibitors for Psoriasis Market Size Forecast by Country (2027-2032) & (US$ Million) Table 135. Europe IL-17 Inhibitors for Psoriasis Market Share Forecast by Country (2027-2032) Table 136. Asia-Pacific IL-17 Inhibitors for Psoriasis Market Size Growth Rate (CAGR) by Country (Units): 2021 VS 2025 VS 2032 Table 137. Asia-Pacific IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026) & (Units) Table 138. Asia-Pacific IL-17 Inhibitors for Psoriasis Sales Market Share by Country (2021-2026) Table 139. Asia-Pacific IL-17 Inhibitors for Psoriasis Sales Forecast by Country (2027-2032) & (Units) Table 140. Asia-Pacific IL-17 Inhibitors for Psoriasis Sales Market Share Forecast by Country (2027-2032) Table 141. Asia-Pacific IL-17 Inhibitors for Psoriasis Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 142. Asia-Pacific IL-17 Inhibitors for Psoriasis Market Size by Country (2021-2026) & (US$ Million) Table 143. Asia-Pacific IL-17 Inhibitors for Psoriasis Market Share by Country (2021-2026) Table 144. Asia-Pacific IL-17 Inhibitors for Psoriasis Market Size Forecast by Country (2027-2032) & (US$ Million) Table 145. Asia-Pacific IL-17 Inhibitors for Psoriasis Market Share Forecast by Country (2027-2032) Table 146. Latin America IL-17 Inhibitors for Psoriasis Market Size Growth Rate (CAGR) by Country (Units): 2021 VS 2025 VS 2032 Table 147. Latin America IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026) & (Units) Table 148. Latin America IL-17 Inhibitors for Psoriasis Sales Market Share by Country (2021-2026) Table 149. Latin America IL-17 Inhibitors for Psoriasis Sales Forecast by Country (2027-2032) & (Units) Table 150. Latin America IL-17 Inhibitors for Psoriasis Sales Market Share Forecast by Country (2027-2032) Table 151. Latin America IL-17 Inhibitors for Psoriasis Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 152. Latin America IL-17 Inhibitors for Psoriasis Market Size by Country (2021-2026) & (US$ Million) Table 153. Latin America IL-17 Inhibitors for Psoriasis Market Share by Country (2021-2026) Table 154. Latin America IL-17 Inhibitors for Psoriasis Market Size Forecast by Country (2027-2032) & (US$ Million) Table 155. Latin America IL-17 Inhibitors for Psoriasis Market Share Forecast by Country (2027-2032) Table 156. Middle East and Africa IL-17 Inhibitors for Psoriasis Market Size Growth Rate (CAGR) by Country (Units): 2021 VS 2025 VS 2032 Table 157. Middle East and Africa IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026) & (Units) Table 158. Middle East and Africa IL-17 Inhibitors for Psoriasis Sales Market Share by Country (2021-2026) Table 159. Middle East and Africa IL-17 Inhibitors for Psoriasis Sales Forecast by Country (2027-2032) & (Units) Table 160. Middle East and Africa IL-17 Inhibitors for Psoriasis Sales Market Share Forecast by Country (2027-2032) Table 161. Middle East and Africa IL-17 Inhibitors for Psoriasis Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 162. Middle East and Africa IL-17 Inhibitors for Psoriasis Market Size by Country (2021-2026) & (US$ Million) Table 163. Middle East and Africa IL-17 Inhibitors for Psoriasis Market Share by Country (2021-2026) Table 164. Middle East and Africa IL-17 Inhibitors for Psoriasis Market Size Forecast by Country (2027-2032) & (US$ Million) Table 165. Middle East and Africa IL-17 Inhibitors for Psoriasis Market Share Forecast by Country (2027-2032) Table 166. Key Raw Materials Table 167. Raw Materials Key Suppliers Table 168. IL-17 Inhibitors for Psoriasis Distributors List Table 169. IL-17 Inhibitors for Psoriasis Customers List Table 170. Research Programs/Design for This Report Table 171. Authors List of This Report Table 172. Secondary Sources Table 173. Primary Sources List of Figures Figure 1. IL-17 Inhibitors for Psoriasis Image Figure 2. Global IL-17 Inhibitors for Psoriasis Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global IL-17 Inhibitors for Psoriasis Market Size (2021-2032) & (US$ Million) Figure 4. Global IL-17 Inhibitors for Psoriasis Sales (2021-2032) & (Units) Figure 5. Ixekizumab Image Figure 6. Global Ixekizumab Sales YoY Growth (2021-2032) & (Units) Figure 7. Secukinumab Image Figure 8. Global Secukinumab Sales YoY Growth (2021-2032) & (Units) Figure 9. Xeligekimab Image Figure 10. Global Xeligekimab Sales YoY Growth (2021-2032) & (Units) Figure 11. Vunakizumab Image Figure 12. Global Vunakizumab Sales YoY Growth (2021-2032) & (Units) Figure 13. Brodalumab Image Figure 14. Global Brodalumab Sales YoY Growth (2021-2032) & (Units) Figure 15. Bimelizumab Image Figure 16. Global Bimelizumab Sales YoY Growth (2021-2032) & (Units) Figure 17. Other Image Figure 18. Global Other Sales YoY Growth (2021-2032) & (Units) Figure 19. Global IL-17 Inhibitors for Psoriasis Market Size Overview by Type (2021-2032) & (US$ Million) Figure 20. Global IL-17 Inhibitors for Psoriasis Market Share by Type 2025 VS 2032 Figure 21. North America IL-17 Inhibitors for Psoriasis Sales Market Share in Volume by Type in 2025 Figure 22. North America IL-17 Inhibitors for Psoriasis Sales Market Share in Value by Type in 2025 Figure 23. Europe IL-17 Inhibitors for Psoriasis Sales Market Share in Volume by Type in 2025 Figure 24. Europe IL-17 Inhibitors for Psoriasis Sales Market Share in Value by Type in 2025 Figure 25. Asia-Pacific IL-17 Inhibitors for Psoriasis Sales Market Share in Volume by Type in 2025 Figure 26. Asia-Pacific IL-17 Inhibitors for Psoriasis Sales Market Share in Value by Type in 2025 Figure 27. Latin America IL-17 Inhibitors for Psoriasis Sales Market Share in Volume by Type in 2025 Figure 28. Latin America IL-17 Inhibitors for Psoriasis Sales Market Share in Value by Type in 2025 Figure 29. Middle East and Africa IL-17 Inhibitors for Psoriasis Sales Market Share in Volume by Type in 2025 Figure 30. Middle East and Africa IL-17 Inhibitors for Psoriasis Sales Market Share in Value by Type in 2025 Figure 31. Global Top 5 and 10 IL-17 Inhibitors for Psoriasis Players Market Share by Revenue in 2025 Figure 32. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 33. Hospital and Clinic Image Figure 34. Global Hospital and Clinic Sales YoY Growth (2021-2032) & (Units) Figure 35. Pharmacy Image Figure 36. Global Pharmacy Sales YoY Growth (2021-2032) & (Units) Figure 37. Other Image Figure 38. Global Other Sales YoY Growth (2021-2032) & (Units) Figure 39. Global IL-17 Inhibitors for Psoriasis Market Size Overview by Application (2021-2032) & (US$ Million) Figure 40. Global IL-17 Inhibitors for Psoriasis Market Share by Application 2025 VS 2032 Figure 41. North America IL-17 Inhibitors for Psoriasis Sales Market Share in Volume by Application in 2025 Figure 42. North America IL-17 Inhibitors for Psoriasis Sales Market Share in Value by Application in 2025 Figure 43. Europe IL-17 Inhibitors for Psoriasis Sales Market Share in Volume by Application in 2025 Figure 44. Europe IL-17 Inhibitors for Psoriasis Sales Market Share in Value by Application in 2025 Figure 45. Asia-Pacific IL-17 Inhibitors for Psoriasis Sales Market Share in Volume by Application in 2025 Figure 46. Asia-Pacific IL-17 Inhibitors for Psoriasis Sales Market Share in Value by Application in 2025 Figure 47. Latin America IL-17 Inhibitors for Psoriasis Sales Market Share in Volume by Application in 2025 Figure 48. Latin America IL-17 Inhibitors for Psoriasis Sales Market Share in Value by Application in 2025 Figure 49. Middle East and Africa IL-17 Inhibitors for Psoriasis Sales Market Share in Volume by Application in 2025 Figure 50. Middle East and Africa IL-17 Inhibitors for Psoriasis Sales Market Share in Value by Application in 2025 Figure 51. North America IL-17 Inhibitors for Psoriasis Sales by Country: 2021 VS 2025 VS 2032 (Units) Figure 52. North America IL-17 Inhibitors for Psoriasis Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. North America IL-17 Inhibitors for Psoriasis Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. North America IL-17 Inhibitors for Psoriasis Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe IL-17 Inhibitors for Psoriasis Sales by Country: 2021 VS 2025 VS 2032 (Units) Figure 56. Europe IL-17 Inhibitors for Psoriasis Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Europe IL-17 Inhibitors for Psoriasis Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Europe IL-17 Inhibitors for Psoriasis Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific IL-17 Inhibitors for Psoriasis Sales by Country: 2021 VS 2025 VS 2032 (Units) Figure 60. Asia-Pacific IL-17 Inhibitors for Psoriasis Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific IL-17 Inhibitors for Psoriasis Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Asia-Pacific IL-17 Inhibitors for Psoriasis Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America IL-17 Inhibitors for Psoriasis Sales by Country: 2021 VS 2025 VS 2032 (Units) Figure 64. Latin America IL-17 Inhibitors for Psoriasis Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Latin America IL-17 Inhibitors for Psoriasis Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Latin America IL-17 Inhibitors for Psoriasis Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa IL-17 Inhibitors for Psoriasis Sales by Country: 2021 VS 2025 VS 2032 (Units) Figure 68. Middle East and Africa IL-17 Inhibitors for Psoriasis Sales Share by Country: 2021 VS 2025 VS 2032 Figure 69. Middle East and Africa IL-17 Inhibitors for Psoriasis Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 70. Middle East and Africa IL-17 Inhibitors for Psoriasis Market Share by Country: 2021 VS 2025 VS 2032 Figure 71. IL-17 Inhibitors for Psoriasis Value Chain Figure 72. Key Raw Materials Price Figure 73. Manufacturing Cost Structure Figure 74. IL-17 Inhibitors for Psoriasis Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Years Considered Figure 78. Research Process Figure 79. Key Executives Interviewed

Scope & coverage.

Types
  • Ixekizumab
  • Secukinumab
  • Xeligekimab
  • Vunakizumab
  • Brodalumab
  • Bimelizumab
  • Other
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • UCB
  • Kyowa Kirin
  • LEO Pharma
  • Ortho Dermatologics
  • Jiangsu Hengrui Pharmaceuticals
  • Eli Lilly
  • Novartis
  • Chongqing Genrix Biopharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global IL-17 Inhibitors for Psoriasis Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global IL-17 Inhibitors for Psoriasis Sales Estimates and Forecasts (2021-2032)
  5. 1.3 IL-17 Inhibitors for Psoriasis Market by Type
  6. 1.3.1 Ixekizumab
  7. 1.3.2 Secukinumab
  8. 1.3.3 Xeligekimab
  9. 1.3.4 Vunakizumab
  10. 1.3.5 Brodalumab
  11. 1.3.6 Bimelizumab
  12. 1.3.7 Other
  13. 1.4 Global IL-17 Inhibitors for Psoriasis Market Size by Type
  14. 1.4.1 Global IL-17 Inhibitors for Psoriasis Market Size Overview by Type (2021-2032)
  15. 1.4.2 Global IL-17 Inhibitors for Psoriasis Historic Market Size Review by Type (2021-2026)
  16. 1.4.3 Global IL-17 Inhibitors for Psoriasis Forecasted Market Size by Type (2027-2032)
  17. 1.5 Key Regions Market Size by Type
  18. 1.5.1 North America IL-17 Inhibitors for Psoriasis Sales Breakdown by Type (2021-2026)
  19. 1.5.2 Europe IL-17 Inhibitors for Psoriasis Sales Breakdown by Type (2021-2026)
  20. 1.5.3 Asia-Pacific IL-17 Inhibitors for Psoriasis Sales Breakdown by Type (2021-2026)
  21. 1.5.4 South America IL-17 Inhibitors for Psoriasis Sales Breakdown by Type (2021-2026)
  22. 1.5.5 Middle East and Africa IL-17 Inhibitors for Psoriasis Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 IL-17 Inhibitors for Psoriasis Industry Trends
  2. 2.2 IL-17 Inhibitors for Psoriasis Industry Drivers
  3. 2.3 IL-17 Inhibitors for Psoriasis Industry Opportunities and Challenges
  4. 2.4 IL-17 Inhibitors for Psoriasis Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by IL-17 Inhibitors for Psoriasis Revenue (2021-2026)
  2. 3.2 Global Top Players by IL-17 Inhibitors for Psoriasis Sales (2021-2026)
  3. 3.3 Global Top Players by IL-17 Inhibitors for Psoriasis Price (2021-2026)
  4. 3.4 Global IL-17 Inhibitors for Psoriasis Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global IL-17 Inhibitors for Psoriasis Major Company Production Sites & Headquarters
  6. 3.6 Global IL-17 Inhibitors for Psoriasis Company, Product Type & Application
  7. 3.7 Global IL-17 Inhibitors for Psoriasis Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global IL-17 Inhibitors for Psoriasis Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 IL-17 Inhibitors for Psoriasis Players Market Share by Revenue in 2025
  11. 3.8.3 2025 IL-17 Inhibitors for Psoriasis Tier 1, Tier 2, and Tier 3
4 IL-17 Inhibitors for Psoriasis Regional Status and Outlook
  1. 4.1 Global IL-17 Inhibitors for Psoriasis Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global IL-17 Inhibitors for Psoriasis Historic Market Size by Region
  3. 4.2.1 Global IL-17 Inhibitors for Psoriasis Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global IL-17 Inhibitors for Psoriasis Sales in Value by Region (2021-2026)
  5. 4.2.3 Global IL-17 Inhibitors for Psoriasis Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global IL-17 Inhibitors for Psoriasis Forecasted Market Size by Region
  7. 4.3.1 Global IL-17 Inhibitors for Psoriasis Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global IL-17 Inhibitors for Psoriasis Sales in Value by Region (2027-2032)
  9. 4.3.3 Global IL-17 Inhibitors for Psoriasis Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 IL-17 Inhibitors for Psoriasis by Application
  1. 5.1 IL-17 Inhibitors for Psoriasis Market by Application
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global IL-17 Inhibitors for Psoriasis Market Size by Application
  6. 5.2.1 Global IL-17 Inhibitors for Psoriasis Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global IL-17 Inhibitors for Psoriasis Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global IL-17 Inhibitors for Psoriasis Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America IL-17 Inhibitors for Psoriasis Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe IL-17 Inhibitors for Psoriasis Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific IL-17 Inhibitors for Psoriasis Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America IL-17 Inhibitors for Psoriasis Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa IL-17 Inhibitors for Psoriasis Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 UCB
  2. 6.1.1 UCB Company Information
  3. 6.1.2 UCB Business Overview
  4. 6.1.3 UCB IL-17 Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 UCB IL-17 Inhibitors for Psoriasis Product Portfolio
  6. 6.1.5 UCB Recent Developments
  7. 6.2 Kyowa Kirin
  8. 6.2.1 Kyowa Kirin Company Information
  9. 6.2.2 Kyowa Kirin Business Overview
  10. 6.2.3 Kyowa Kirin IL-17 Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Kyowa Kirin IL-17 Inhibitors for Psoriasis Product Portfolio
  12. 6.2.5 Kyowa Kirin Recent Developments
  13. 6.3 LEO Pharma
  14. 6.3.1 LEO Pharma Company Information
  15. 6.3.2 LEO Pharma Business Overview
  16. 6.3.3 LEO Pharma IL-17 Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 LEO Pharma IL-17 Inhibitors for Psoriasis Product Portfolio
  18. 6.3.5 LEO Pharma Recent Developments
  19. 6.4 Ortho Dermatologics
  20. 6.4.1 Ortho Dermatologics Company Information
  21. 6.4.2 Ortho Dermatologics Business Overview
  22. 6.4.3 Ortho Dermatologics IL-17 Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Ortho Dermatologics IL-17 Inhibitors for Psoriasis Product Portfolio
  24. 6.4.5 Ortho Dermatologics Recent Developments
  25. 6.5 Jiangsu Hengrui Pharmaceuticals
  26. 6.5.1 Jiangsu Hengrui Pharmaceuticals Company Information
  27. 6.5.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  28. 6.5.3 Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Product Portfolio
  30. 6.5.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  31. 6.6 Eli Lilly
  32. 6.6.1 Eli Lilly Company Information
  33. 6.6.2 Eli Lilly Business Overview
  34. 6.6.3 Eli Lilly IL-17 Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Eli Lilly IL-17 Inhibitors for Psoriasis Product Portfolio
  36. 6.6.5 Eli Lilly Recent Developments
  37. 6.7 Novartis
  38. 6.7.1 Novartis Company Information
  39. 6.7.2 Novartis Business Overview
  40. 6.7.3 Novartis IL-17 Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Novartis IL-17 Inhibitors for Psoriasis Product Portfolio
  42. 6.7.5 Novartis Recent Developments
  43. 6.8 Chongqing Genrix Biopharmaceutical
  44. 6.8.1 Chongqing Genrix Biopharmaceutical Company Information
  45. 6.8.2 Chongqing Genrix Biopharmaceutical Business Overview
  46. 6.8.3 Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Product Portfolio
  48. 6.8.5 Chongqing Genrix Biopharmaceutical Recent Developments
7 North America by Country
  1. 7.1 North America IL-17 Inhibitors for Psoriasis Sales by Country
  2. 7.1.1 North America IL-17 Inhibitors for Psoriasis Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026)
  4. 7.1.3 North America IL-17 Inhibitors for Psoriasis Sales Forecast by Country (2027-2032)
  5. 7.2 North America IL-17 Inhibitors for Psoriasis Market Size by Country
  6. 7.2.1 North America IL-17 Inhibitors for Psoriasis Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America IL-17 Inhibitors for Psoriasis Market Size by Country (2021-2026)
  8. 7.2.3 North America IL-17 Inhibitors for Psoriasis Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe IL-17 Inhibitors for Psoriasis Sales by Country
  2. 8.1.1 Europe IL-17 Inhibitors for Psoriasis Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026)
  4. 8.1.3 Europe IL-17 Inhibitors for Psoriasis Sales Forecast by Country (2027-2032)
  5. 8.2 Europe IL-17 Inhibitors for Psoriasis Market Size by Country
  6. 8.2.1 Europe IL-17 Inhibitors for Psoriasis Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe IL-17 Inhibitors for Psoriasis Market Size by Country (2021-2026)
  8. 8.2.3 Europe IL-17 Inhibitors for Psoriasis Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific IL-17 Inhibitors for Psoriasis Sales by Country
  2. 9.1.1 Asia-Pacific IL-17 Inhibitors for Psoriasis Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific IL-17 Inhibitors for Psoriasis Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific IL-17 Inhibitors for Psoriasis Market Size by Country
  6. 9.2.1 Asia-Pacific IL-17 Inhibitors for Psoriasis Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific IL-17 Inhibitors for Psoriasis Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific IL-17 Inhibitors for Psoriasis Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America IL-17 Inhibitors for Psoriasis Sales by Country
  2. 10.1.1 South America IL-17 Inhibitors for Psoriasis Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026)
  4. 10.1.3 South America IL-17 Inhibitors for Psoriasis Sales Forecast by Country (2027-2032)
  5. 10.2 South America IL-17 Inhibitors for Psoriasis Market Size by Country
  6. 10.2.1 South America IL-17 Inhibitors for Psoriasis Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America IL-17 Inhibitors for Psoriasis Market Size by Country (2021-2026)
  8. 10.2.3 South America IL-17 Inhibitors for Psoriasis Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa IL-17 Inhibitors for Psoriasis Sales by Country
  2. 11.1.1 Middle East and Africa IL-17 Inhibitors for Psoriasis Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa IL-17 Inhibitors for Psoriasis Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa IL-17 Inhibitors for Psoriasis Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa IL-17 Inhibitors for Psoriasis Market Size by Country
  6. 11.2.1 Middle East and Africa IL-17 Inhibitors for Psoriasis Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa IL-17 Inhibitors for Psoriasis Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa IL-17 Inhibitors for Psoriasis Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 IL-17 Inhibitors for Psoriasis Value Chain Analysis
  2. 12.1.1 IL-17 Inhibitors for Psoriasis Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 IL-17 Inhibitors for Psoriasis Production Mode & Process
  7. 12.2 IL-17 Inhibitors for Psoriasis Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 IL-17 Inhibitors for Psoriasis Distributors
  10. 12.2.3 IL-17 Inhibitors for Psoriasis Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst